Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00633321 · ClinicalTrials.gov registry record · Phase 2
Study of TA-NIC to Assess the Efficacy and Safety of the Vaccine as an Aid to Smoking Cessation
A Phase 2 study of Smoking, sponsored by Celtic Pharma Development Services.
- Completed
- Registry status
- Phase 2
- Development phase
- 522
- Enrollment target
- 9
- Study locations
NCT00633321: Completed Phase 2 study of Smoking, sponsored by Celtic Pharma Development Services.
NCT00633321 is a Phase 2 study of Smoking that has completed, run by Celtic Pharma Development Services. The registered enrollment target is 522 participants, above the 451-participant average among 123 other Smoking trials with a reported enrollment target (16% higher). The trial reports 9 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00633321, a Phase 2 study of Smoking, has completed, sponsored by Celtic Pharma Development Services.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 522 participants
- Enrollment target
- 9
- Study locations
Study Summary
Over 1 billion people worldwide smoke, resulting in an estimated 4 million deaths annually from smoking-related disease.1 Persistent and long-term smoking leads to an increased risk of cardiovascular damage, respiratory disease, and a higher incidence of a variety of cancers; but for smokers who can quit there is an immediate and significant beneficial impact on their health and life expectancy. Cigarette smoking remains the leading preventable cause of death in the United States (US), accounting for approximately 1 of every 5 deaths (438,000 people) each year. This Phase 2 study will investigate the efficacy and tolerability of 2 doses of TA-NIC compared to placebo as an aid to smoking cessation in smokers who are motivated to quit.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL TA-NIC
Study Locations (9)
Maryland
- Columbia Medical Practice - Columbia
- Centennial Medical Group - Elkridge
Texas
- Benchmark Research - Austin
- Benchmark Research - Fort Worth - Fort Worth
California
- Benchmark Research - Sacramento
Louisiana
- Benchmark Research - Metairie
Minnesota
- Mayo Clinic - Rochester
New Jersey
- CNS Research Institute, P.C. - Clementon
Pennsylvania
- CRI Worldwide, LLC Kirkbride Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 522 participants |
| Start Date | 2007-05 |
| Est. Completion | 2009-02 |
| Phase | Phase 2 |
What the finished NCT00633321 record still lists
NCT00633321 is an interventional study that assigns participants to a tested intervention. The registered 522 participants enrollment target is mid-sized for trials with a published cap, above the 451-participant average among 123 other Smoking trials with a reported enrollment target (16% higher).
The record links to 1 condition, with Smoking appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00633321 lists 9 locations in 7 states (Maryland, Texas, California).
Frequently Asked Questions
What is clinical trial NCT00633321 about?
NCT00633321 is a clinical study titled "Study of TA-NIC to Assess the Efficacy and Safety of the Vaccine as an Aid to Smoking Cessation". Over 1 billion people worldwide smoke, resulting in an estimated 4 million deaths annually from smoking-related disease.1 Persistent and long-term smoking leads to an increased risk of cardiovascular damage, respiratory disease, and a higher incidence of a variety of cancers; but for smokers who can...
What is the current status of trial NCT00633321?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 522 participants. The study started on 2007-05. Estimated completion is 2009-02.
What conditions does trial NCT00633321 study?
This clinical trial studies the following conditions: Smoking.
What interventions are being tested in trial NCT00633321?
The interventions under investigation include: Placebo (BIOLOGICAL), TA-NIC (BIOLOGICAL).
Who is sponsoring clinical trial NCT00633321?
This trial is sponsored by Celtic Pharma Development Services, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00633321 being conducted?
This trial has 9 study locations across California, Louisiana, Maryland, Minnesota, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoking
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00633321's enrollment target sits among peer trials
522 30th of 123 higher than 94 of 123 other Smoking trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Smoking trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Potential of Kava in Enabling Tobacco Cessation - Its Holistic Effects in Managing Stress and Insomnia Associated With Abstinence
RECRUITING · Phase 2
-
A Study of Brenipatide in Adults Who Quit Smoking Cigarettes and Want to Avoid Relapse
RECRUITING · Phase 2
-
App for Reducing Cravings to Smoke
RECRUITING · Phase 2
-
Reducing Tobacco-associated Lung Cancer Risk: A Randomized Clinical Trial of AB-free Kava
ACTIVE NOT RECRUITING · Phase 2
-
Proactive Health Intervention for Tobacco Users (Get PHIT)
COMPLETED · Phase 2
-
Computer-Assisted Intervention for Smoking During Pregnancy
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06835686 · 522 participants · NA
Collaborative Multi-level Obesity Intervention Engaging Underserved Communities Trial
- NCT06894212 · 522 participants · Phase 3
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
- NCT03526835 · 523 participants · Phase 1
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
- NCT04580134 · 524 participants · Phase 4
CLOZAPINE Response in Biotype-1
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia